Revenue Summary of Emergent BioSolutions Inc.

Emergent BioSolutions Inc.'s latest annual revenue in 2023 was 1.04 Billion USD , down -6.39% from previous year.
Emergent BioSolutions Inc.'s latest quarterly revenue in 2024 Q2 was 254.7 Million USD , down -15.21% from previous quarter.
Emergent BioSolutions Inc. reported a annual revenue of 1.12 Billion USD in annual revenue 2022, down -37.47% from previous year.
Emergent BioSolutions Inc. reported a annual revenue of 1.79 Billion USD in annual revenue 2021, up 15.26% from previous year.
Emergent BioSolutions Inc. reported a quarterly revenue of 300.4 Million USD for 2024 Q1, up 8.6% from previous quarter.
Emergent BioSolutions Inc. reported a quarterly revenue of 276.6 Million USD for 2023 Q4, up 2.26% from previous quarter.

Annual Revenue Chart of Emergent BioSolutions Inc. (2023 - 2001)

Historical Annual Revenue of Emergent BioSolutions Inc. (2023 - 2001)

Year	Revenue	Revenue Growth
2023	1.04 Billion USD	-6.39%
2022	1.12 Billion USD	-37.47%
2021	1.79 Billion USD	15.26%
2020	1.55 Billion USD	40.63%
2019	1.1 Billion USD	41.36%
2018	782.4 Million USD	39.5%
2017	560.87 Million USD	14.75%
2016	488.78 Million USD	-6.5%
2015	522.78 Million USD	16.14%
2014	450.13 Million USD	43.93%
2013	312.74 Million USD	10.95%
2012	281.88 Million USD	3.11%
2011	273.38 Million USD	-4.47%
2010	286.17 Million USD	21.89%
2009	234.78 Million USD	31.49%
2008	178.55 Million USD	-2.38%
2007	182.91 Million USD	19.76%
2006	152.73 Million USD	16.87%
2005	130.68 Million USD	56.52%
2004	83.49 Million USD	49.71%
2003	55.76 Million USD	-28.99%
2002	78.54 Million USD	73.35%
2001	45.3 Million USD	0.0%

Year	Revenue	Revenue Growth
2024 Q2	254.7 Million USD	-15.21%
2024 Q1	300.4 Million USD	8.6%
2023 Q4	276.6 Million USD	2.26%
2023 Q1	165.1 Million USD	-50.08%
2023 Q2	337.9 Million USD	104.66%
2023 FY	1.04 Billion USD	-6.39%
2023 Q3	270.5 Million USD	-19.95%
2022 Q4	330.7 Million USD	37.79%
2022 Q2	242.7 Million USD	-21.07%
2022 Q3	240 Million USD	-1.11%
2022 Q1	307.5 Million USD	-57.48%
2022 FY	1.12 Billion USD	-37.47%
2021 Q4	723.2 Million USD	119.82%
2021 FY	1.79 Billion USD	15.26%
2021 Q1	343 Million USD	-41.17%
2021 Q2	397.5 Million USD	15.89%
2021 Q3	329 Million USD	-17.23%
2020 Q3	385.2 Million USD	-2.41%
2020 Q2	394.7 Million USD	105.04%
2020 Q1	192.5 Million USD	-46.59%
2020 FY	1.55 Billion USD	40.63%
2020 Q4	583 Million USD	51.35%
2019 Q3	311.8 Million USD	28.21%
2019 FY	1.1 Billion USD	41.36%
2019 Q1	190.6 Million USD	-29.59%
2019 Q2	243.2 Million USD	27.6%
2019 Q4	360.4 Million USD	15.59%
2018 Q2	220.2 Million USD	86.9%
2018 Q4	270.7 Million USD	55.89%
2018 FY	782.4 Million USD	39.5%
2018 Q1	117.81 Million USD	-39.21%
2018 Q3	173.65 Million USD	-21.14%
2017 Q3	149.43 Million USD	48.29%
2017 FY	560.87 Million USD	14.75%
2017 Q1	116.85 Million USD	-22.95%
2017 Q2	100.77 Million USD	-13.77%
2017 Q4	193.8 Million USD	29.7%
2016 FY	488.78 Million USD	-6.5%
2016 Q2	101.48 Million USD	-8.57%
2016 Q4	151.66 Million USD	6.12%
2016 Q3	142.91 Million USD	40.82%
2016 Q1	111 Million USD	-33.97%
2015 Q4	168.1 Million USD	1.92%
2015 Q1	63.63 Million USD	-57.0%
2015 FY	522.78 Million USD	16.14%
2015 Q2	126.11 Million USD	98.19%
2015 Q3	164.94 Million USD	30.79%
2014 Q4	147.97 Million USD	7.26%
2014 FY	450.13 Million USD	43.93%
2014 Q2	110.32 Million USD	104.75%
2014 Q1	53.88 Million USD	-45.08%
2014 Q3	137.95 Million USD	25.04%
2013 Q2	82.43 Million USD	91.27%
2013 Q3	89.1 Million USD	8.09%
2013 FY	312.74 Million USD	10.95%
2013 Q4	98.1 Million USD	10.11%
2013 Q1	43.1 Million USD	-54.44%
2012 Q1	50.31 Million USD	-53.39%
2012 Q2	70.37 Million USD	39.89%
2012 Q3	66.59 Million USD	-5.38%
2012 FY	281.88 Million USD	3.11%
2012 Q4	94.6 Million USD	42.07%
2011 Q1	18.53 Million USD	-82.05%
2011 Q3	58.76 Million USD	-33.33%
2011 Q2	88.14 Million USD	375.59%
2011 FY	273.38 Million USD	-4.47%
2011 Q4	107.94 Million USD	83.7%
2010 Q1	46.8 Million USD	-13.02%
2010 Q4	103.24 Million USD	39.55%
2010 FY	286.17 Million USD	21.89%
2010 Q3	73.98 Million USD	19.07%
2010 Q2	62.13 Million USD	32.77%
2009 Q3	43.27 Million USD	-40.88%
2009 Q2	73.19 Million USD	13.44%
2009 FY	234.78 Million USD	31.49%
2009 Q1	64.51 Million USD	80.47%
2009 Q4	53.8 Million USD	24.34%
2008 Q4	35.75 Million USD	-36.84%
2008 Q1	42.72 Million USD	-52.34%
2008 Q2	43.48 Million USD	1.79%
2008 FY	178.55 Million USD	-2.38%
2008 Q3	56.59 Million USD	30.16%
2007 Q1	26.44 Million USD	-69.56%
2007 Q4	89.63 Million USD	105.38%
2007 Q3	43.64 Million USD	88.23%
2007 Q2	23.18 Million USD	-12.33%
2007 FY	182.91 Million USD	19.76%
2006 Q1	21.94 Million USD	-49.88%
2006 FY	152.73 Million USD	16.87%
2006 Q4	86.88 Million USD	295.89%
2006 Q3	21.94 Million USD	0.0%
2006 Q2	21.94 Million USD	0.0%
2005 Q2	28.96 Million USD	0.0%
2005 Q3	28.96 Million USD	0.0%
2005 FY	130.68 Million USD	56.52%
2005 Q1	28.96 Million USD	38.78%
2005 Q4	43.78 Million USD	51.17%
2004 Q3	20.87 Million USD	0.0%
2004 Q2	20.87 Million USD	0.0%
2004 Q4	20.87 Million USD	-0.0%
2004 FY	83.49 Million USD	49.71%
2004 Q1	20.87 Million USD	0.0%
2003 FY	55.76 Million USD	-28.99%
2002 FY	78.54 Million USD	73.35%
2001 FY	45.3 Million USD	0.0%
2001 Q4	330.7 Million USD	0.52%
2001 Q3	329 Million USD	-2.63%
2001 Q2	337.9 Million USD	9.89%
2001 Q1	307.5 Million USD	-7.02%
2000 Q4	330.7 Million USD	0.0%

Peer Revenue Comparison of Emergent BioSolutions Inc.

Name	Revenue	Revenue Difference
Amneal Pharmaceuticals, Inc.	2.39 Billion USD	56.162%
Bausch Health Companies Inc.	8.75 Billion USD	88.018%
Catalent, Inc.	4.38 Billion USD	76.049%
Elanco Animal Health Incorporated	4.41 Billion USD	76.244%
Perrigo Company plc	4.65 Billion USD	77.462%
Teva Pharmaceutical Industries Limited	15.84 Billion USD	93.378%
Zoetis Inc.	8.54 Billion USD	87.719%

Global Stocks Search

Emergent BioSolutions Inc. (EBS)

Revenue Summary of Emergent BioSolutions Inc.

Annual Revenue Chart of Emergent BioSolutions Inc. (2023 - 2001)

Historical Annual Revenue of Emergent BioSolutions Inc. (2023 - 2001)

Peer Revenue Comparison of Emergent BioSolutions Inc.